Association of serum glypican-4 levels with cardiovascular risk predictors in women with polycystic ovary syndrome – a pilot study

References

• Zhu HJ, Pan H, Cui Y, et al. The changes of serum glypican 4 in obese patients with different glucose metabolism status. J Clin Endocrinol Metab 2014;99:E2697–701
   Google Scholar
• Tamori Y, Kasuga M. Glypican-4 is a new comer of adipokines working as insulin sensitizer. J Diabet Invest 2013;4:250–1
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Gesta S, Lee KY, et al. Adipose depots possess unique developmental gene signatures. Obesity 2010;18:872–8
   PubMed Web of Science ®Google Scholar
• Ussar S, Bezy O, Blüher M, Kahn CR. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 2012;61:2289–98
   PubMed Web of Science ®Google Scholar
• Yoo HJ, Hwang SY, Cho GJ, et al. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013;98:2897–901
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Isaoglu U, Delibas IB, Kadanali S. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res 2011;37:1020–6
   PubMed Web of Science ®Google Scholar
• Głuszak O, Stopińska-Głuszak U, Glinicki P, et al. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinology 2012;2012:1–7. doi: 10.5402/2012/569862
   Google Scholar
• Kar S. Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: a prospective study of PCOS women. J Hum Reprod Sci 2013;6:194–200
   PubMedGoogle Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). J Hum Reprod Sci 2004;19:41–7
   Google Scholar
• Conway G, Dewailly D, Diamantis-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:P1–29
   PubMed Web of Science ®Google Scholar
• Markopoulos MC, Valsamakis G, Kouskouni E, et al. Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. Eur J Endocrinol 2012;168:83–90
   PubMed Web of Science ®Google Scholar
• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. J Hum Reprod Sci Update 2010;16:347–63
   PubMed Web of Science ®Google Scholar
• Li K, Xu X, Hu W, et al. Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2014;51:981–90
   PubMed Web of Science ®Google Scholar
• Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92:2500–5
   PubMed Web of Science ®Google Scholar
• De Groot PCM, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. J Hum Reprod Sci 2011;17:495–500
   Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88
   PubMed Web of Science ®Google Scholar
• Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:801–14
   PubMed Web of Science ®Google Scholar
• Pouliot M-C, Despres J-P, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460–8
   PubMed Web of Science ®Google Scholar
• Carey DG, Jenkins AB, Campbell MV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633–8
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Global Heart 2013;1:11–23
   Google Scholar
• Lwow F, Dunajska K, Milewicz A, et al. Effect of moderate-intensity exercise on oxidative stress indices in metabolically healthy obese and metabolically unhealthy obese phenotypes in postmenopausal women: a pilot study. Menopause 2011;18:646–53
   PubMed Web of Science ®Google Scholar
• Lenarcik-Kabza A, Laczmański L, Milewicz A, et al. The influence of endocannabinoid receptor 1 gene variations on anthropometric and metabolic parameters of women with polycystic ovary syndrome. Endokrynologia Polska 2014;65:181–8
   PubMed Web of Science ®Google Scholar
• Wallace TR, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–95
   PubMed Web of Science ®Google Scholar
• Gesta S, Blüher M, Yamamoto Y, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA 2006;103:6676–81
   PubMed Web of Science ®Google Scholar
• Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699–713
   PubMed Web of Science ®Google Scholar
• O’Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014;99:1027–36
   PubMed Web of Science ®Google Scholar